Skip to content
AIM ImmunoTech Inc. Logo AIM ImmunoTech Inc. Logo
  • COMPANY
  • PRODUCTS
  • R & D
    • Product Candidates Overview
    • Pipeline
    • Orphan Drug Designations
  • PARTNERING
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • XBRL Filings
    • Stockholder Meeting
    • Corporate Governance
    • Email Alerts
    • Investor Contact
  • BLOG
  • CONTACT

Stockholder Meeting

Stockholder MeetingAIM ImmunoTech2019-08-27T12:16:39-04:00

Latest News

  • Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials
  • Prostate Cancer News Today Provides an Ampligen Upate
  • Ovarian Cancer News Today Updates Readers on Ampligen Trials

Privacy / Terms of Use

  • Terms Of Use
  • Investor Contact

Tweets by AIM Immuno

© Copyright    |    All Rights Reserved   |   AIM ImmunoTech Inc.   |   Privacy Policy   |   Terms of Use
FacebookTwitterYouTubeLinkedIn
Hemispherx Biopharma, Inc. (NYSE:HEB) is now known as AIM ImmunoTech Inc. (NYSE:AIM)Accept